Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma

Jii Bum Lee, Hyung Soon Park, Sejung Park, Hyo Jin Lee, Kyung A. Kwon, Young Jin Choi, Yu Jung Kim, Chung Mo Nam, Nam Hoon Cho, Beodeul Kang, Hyun Cheol Chung, Sun Young Rha

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)


Purpose Temsirolimus is effective in the treatment for metastatic non-clear cell renal cell carcinoma (nccRCC) with poor prognosis. We aim to investigate the efficacy and tolerability of temsirolimus in treatment of naïve Asian patients with metastatic/recurrent nccRCC. Materials and Methods From January 2008 to July 2017, data of treatment-naïve, metastatic/recurrent nccRCC patients, who were treated with temsirolimus according to the standard protocol, were collected. The primary end-point was progression-free survival (PFS). Secondary end points were overall survival (OS), objective response rate (ORR), and tolerability of temsirolimus. Results Forty-four metastatic/recurrent nccRCC patients, 10 from prospective and 34 from retrospective groups, were enrolled; 24 patients (54%) were papillary type, and other histology subtypes included 11 chromophobes (25%), two collecting ducts (5%), one Xp11.2 translocation (2%), and six others (14%). The median PFS and OS were 7.6 months and 17.6 months, respectively. ORR was 11% and disease control rate was 83%. Patients with prior nephrectomy had longer PFS (hazard ratio [HR], 0.16; 95% confidence interval [CI], 0.06 to 0.42; p 0.001) and OS (HR, 0.15; 95% CI, 0.05 to 0.45; p 0.001). Compared to favorable/ intermediate prognosis group, poor prognosis group had shorter median PFS (4.7 months vs. 7.6 months [HR, 2.91; 95% CI, 1.39 to 6.12; p=0.005]) and median OS (9.2 months vs. 17.6 months [HR, 2.84; 95% CI, 1.23 to 6.56; p=0.015]). Conclusion Temsirolimus not only benefits poor-risk nccRCC patients, but it is also effective in favorable or intermediate-risk group in Asians. Temsirolimus was well-Tolerated with manageable adverse events.

Original languageEnglish
Pages (from-to)1578-1588
Number of pages11
JournalCancer Research and Treatment
Issue number4
Publication statusPublished - 2019 Oct 1

Bibliographical note

Publisher Copyright:
© 2019 Korean Cancer Association. All rights reserved.

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma'. Together they form a unique fingerprint.

Cite this